169 related articles for article (PubMed ID: 30057405)
21. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.
Dupont J; Wang X; Marshall DS; Leitao M; Hedvat CV; Hummer A; Thaler H; O'Reilly RJ; Soslow RA
Gynecol Oncol; 2004 Aug; 94(2):449-55. PubMed ID: 15297187
[TBL] [Abstract][Full Text] [Related]
22. Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours.
Athanassiadou P; Petrakakou E; Sakelariou V; Zerva C; Liossi A; Michalas S; Athanassiades P
Eur J Cancer Prev; 1998 Jun; 7(3):225-31. PubMed ID: 9696931
[TBL] [Abstract][Full Text] [Related]
23. Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience.
Lee S; Piskorz AM; Le Page C; Mes Masson AM; Provencher D; Huntsman D; Chen W; Swanson PE; Gilks CB; Köbel M
Int J Gynecol Pathol; 2016 May; 35(3):209-21. PubMed ID: 26598982
[TBL] [Abstract][Full Text] [Related]
24. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
25. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer.
Dong Y; Walsh MD; McGuckin MA; Cummings MC; Gabrielli BG; Wright GR; Hurst T; Khoo SK; Parsons PG
Int J Cancer; 1997 Aug; 74(4):407-15. PubMed ID: 9291430
[TBL] [Abstract][Full Text] [Related]
26. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
28. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
29. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
[TBL] [Abstract][Full Text] [Related]
30. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas.
Høgdall EV; Christensen L; Høgdall CK; Frederiksen K; Gayther S; Blaakaer J; Jacobs IJ; Kjaer SK
APMIS; 2008 May; 116(5):400-9. PubMed ID: 18452430
[TBL] [Abstract][Full Text] [Related]
31. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.
Diebold J; Baretton G; Felchner M; Meier W; Dopfer K; Schmidt M; Löhrs U
Am J Clin Pathol; 1996 Mar; 105(3):341-9. PubMed ID: 8602616
[TBL] [Abstract][Full Text] [Related]
32. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
33. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.
Köbel M; Reuss A; du Bois A; Kommoss S; Kommoss F; Gao D; Kalloger SE; Huntsman DG; Gilks CB
J Pathol; 2010 Oct; 222(2):191-8. PubMed ID: 20629008
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
35. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
36. Wilms' tumor 1 (WT1) as a prognosis factor in gynecological cancers: A meta-analysis.
Lu J; Gu Y; Li Q; Zhong H; Wang X; Zheng Z; Hu W; Wen L
Medicine (Baltimore); 2018 Jul; 97(28):e11485. PubMed ID: 29995811
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
38. Wilms' tumor 1 antigen immunoreactivity in epithelial ovarian cancer - diagnostic and prognostic value.
Zarychta E; Lepinay K; Szubert S; Jozwicki J; Misiak J; Brozyna AA; Kosinska-Kaczynska K; Lewandowska A; Malicka E; Makarewicz A; Rhone P; Jozwicki W
Folia Histochem Cytobiol; 2020; 58(3):198-207. PubMed ID: 32960974
[TBL] [Abstract][Full Text] [Related]
39. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
[TBL] [Abstract][Full Text] [Related]
40. High Wilms' tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma.
Scattone A; Serio G; Marzullo A; Nazzaro P; Corsi F; Cocca MP; Mattoni M; Punzi A; Gentile M; Buonadonna AL; Pennella A
Histopathology; 2012 Feb; 60(3):472-81. PubMed ID: 22276610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
